{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:31:53Z","timestamp":1785461513289,"version":"3.56.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109356"],"award-info":[{"award-number":["JP19ek0109356"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109394"],"award-info":[{"award-number":["JP19ek0109394"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["19FC1007"],"award-info":[{"award-number":["19FC1007"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.pharmthera.2020.107669","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T10:59:35Z","timestamp":1598007575000},"page":"107669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) focusing on clinical and laboratory biomarkers"],"prefix":"10.1016","volume":"218","author":[{"given":"Junji","family":"Yamauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107669_bb0005","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF00810351","article-title":"Neopterin concentrations in serum and cerebrospinal fluid in HTLV-I infected individuals","volume":"239","author":"Ali","year":"1992","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0015","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1093\/brain\/awt183","article-title":"Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy","volume":"136","author":"Ando","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1590\/S0004-282X1993000300005","article-title":"Intravenous methylprednisolone in HTLV-I associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"51","author":"Araujo","year":"1993","journal-title":"Arquivos de Neuro-Psiquiatria"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00042560-199812150-00014","article-title":"HTLV-I-associated myelopathy\/tropical spastic paraparesis in Brazil: A nationwide survey","volume":"19","author":"Ara\u00fajo","year":"1998","journal-title":"Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0030","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1172\/JCI75250","article-title":"HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells","volume":"124","author":"Araya","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/13550280701397627","article-title":"Safety and efficacy of interferon-\u03b1 in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy","volume":"13","author":"Arimura","year":"2007","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0040","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ana.25072","article-title":"Imaging spinal cord atrophy in progressive myelopathies: HTLV-I-associated neurological disease (HAM\/TSP) and multiple sclerosis (MS)","volume":"82","author":"Azodi","year":"2017","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0045","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"1","author":"Bangham","year":"2015","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13365-014-0249-3","article-title":"Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM\/TSP patients and identification of viral mutations","volume":"20","author":"Brunetto","year":"2014","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Experimental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0451-x","article-title":"Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net)","volume":"11","author":"Coler-Reilly","year":"2016","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0065","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s13311-017-0533-z","article-title":"Effectiveness of daily prednisolone to slow progression of human T-lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis: A multicenter retrospective cohort study","volume":"14","author":"Coler-Reilly","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0070","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/blood-2012-07-445593","article-title":"HTLV-1-infected T cells contain a single integrated provirus in natural infection","volume":"120","author":"Cook","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-015-0236-7","article-title":"Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients","volume":"13","author":"Cook","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.01.004","article-title":"Corticosteroid therapy in TSP\/HAM patients: The results from a 10-year open cohort","volume":"269","author":"Croda","year":"2008","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0085","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/aid.2006.22.931","article-title":"Proposal for diagnostic criteria of tropical spastic paraparesis\/HTLV-I-associated myelopathy (TSP\/HAM)","volume":"22","author":"De Castro-Costa","year":"2006","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.freeradbiomed.2017.11.022","article-title":"Neopterin preconditioning prevents inflammasome activation in mammalian astrocytes","volume":"115","author":"de Paula Martins","year":"2018","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/aid.2012.0132","article-title":"Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases","volume":"29","author":"Demontis","year":"2013","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.51.6.769","article-title":"Primary Sjogren\u2019s syndrome with antibodies to HTLV-I: Clinical and laboratory features","volume":"51","author":"Eguchi","year":"1992","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0105","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2011-11-390807","article-title":"Quantitative differences in HTLV-I antibody responses: Classification and relative risk assessment for asymptomatic carriers and ATL and HAM\/TSP patients from Jamaica","volume":"119","author":"Enose-Akahata","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0110","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3389\/fmicb.2017.02563","article-title":"Role of HTLV-1 tax and HBZ in the pathogenesis of HAM\/TSP","volume":"8","author":"Enose-Akahata","year":"2017","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007042","article-title":"Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases","volume":"14","author":"Enose-Akahata","year":"2018","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0120","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood.V80.4.1012.1012","article-title":"Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP)","volume":"80","author":"Furukawa","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0125","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"326","author":"Gessain","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0135","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood.V99.9.3335","article-title":"High frequencies of Th1-type CD4+ T cells specific to HTLV-1 Env and tax proteins in patients with HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"99","author":"Goon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0140","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/423957","article-title":"Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1\u2013associated tropical spastic paraparesis","volume":"39","author":"Gotuzzo","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0145","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1073\/pnas.95.13.7568","article-title":"Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM\/TSP patients","volume":"95","author":"Greten","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2249.2006.03150.x","article-title":"Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)\/tropical spastic paraparesis (HAM\/TSP) disease from HTLV-1 carrier state","volume":"145","author":"Guerreiro","year":"2006","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0625.1999.tb00367.x","article-title":"Neopterin: A review","volume":"8","author":"Hamerlinck","year":"1999","journal-title":"Experimental Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0160","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","article-title":"Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera","volume":"78","author":"Hinuma","year":"1981","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1084\/jem.160.1.310","article-title":"Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma","volume":"160","author":"Huber","year":"1984","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1080115","article-title":"Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton","volume":"299","author":"Igakura","year":"2003","journal-title":"Science."},{"key":"10.1016\/j.pharmthera.2020.107669_bb0175","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0306-9877(93)90111-3","article-title":"An autoaggressive process against bystander tissues in HTLV-I-infected individuals: A possible pathomechanism of HAMTSP","volume":"41","author":"Ijichi","year":"1993","journal-title":"Medical Hypotheses"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0180","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0185","first-page":"199","article-title":"Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells","volume":"7","author":"Ishihara","year":"1994","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0190","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized aanti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0195","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","article-title":"Interferon-alpha is effective in HTLV-I-associated myelopathy: A multicenter, randomized, double-blind, controlled trial","volume":"46","author":"Izumo","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/348245a0","article-title":"Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease","volume":"348","author":"Jacobson","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1423-0410.1987.tb02987.x","article-title":"Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors","volume":"52","author":"Kamihira","year":"1987","journal-title":"Vox Sanguinis"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/ICU.0b013e328358b9ec","article-title":"HTLV infection and the eye","volume":"23","author":"Kamoi","year":"2012","journal-title":"Current Opinion in Ophthalmology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0215","first-page":"1096","article-title":"The risk of development of HTLV-1-associated myelopathy\/tropical spastic paraparesis among persons infected with HTLV-1","volume":"3","author":"Kaplan","year":"1990","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0220","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0022-510X(91)90192-A","article-title":"Leukoencephalopathy in HTLV-I-associated myelopathy\/tropical spastic paraparesis: MRI analysis and a two-year follow-up study after corticosteroid therapy","volume":"106","author":"Kira","year":"1991","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0230","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0022-510X(92)90215-7","article-title":"Antibody titers to HTLV-I-p40 tax protein and gag-env hybrid protein in HTLV-I-associated myelopathy\/tropical spastic paraparesis: Correlation with increased HTLV-I proviral DNA load","volume":"107","author":"Kira","year":"1992","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0235","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00868998","article-title":"Diversity of intrathecal antibody synthesis against HTLV-I and its relation to HTLV-I associated myelopathy","volume":"243","author":"Kitze","year":"1996","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0240","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1089\/08892220050193182","article-title":"Increased HTLV type 1 tax-specific CD8+ cells in HTLV type 1-associated myelopathy\/tropical spastic paraparesis: Correlation with HTLV type 1 proviral load","volume":"16","author":"Kubota","year":"2000","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0022-510X(95)00142-O","article-title":"A follow-up study on spastic paraparesis in Japanese HAM\/TSP","volume":"132","author":"Kuroda","year":"1995","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0250","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2009.10.021","article-title":"Human T-lymphotrophic virus type 1-associated infective dermatitis: A comprehensive review","volume":"64","author":"Lee","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0255","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1086\/429962","article-title":"Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: A new criterion for the diagnosis of HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"191","author":"Lezin","year":"2005","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0260","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/423941","article-title":"Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I","volume":"190","author":"Li","year":"2004","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0265","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/jnnp.2004.035709","article-title":"Gender influence on the progression of HTLV-I associated myelopathy\/tropical spastic paraparesis","volume":"76","author":"Lima","year":"2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0270","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/13550280701510096","article-title":"Subacute progression of human T-lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis","volume":"13","author":"Lima","year":"2007","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0275","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.24213","article-title":"In vivo imaging of spinal cord atrophy in neuroinflammatory diseases","volume":"76","author":"Liu","year":"2014","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0280","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/v3050469","article-title":"Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors","volume":"3","author":"Macchi","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0285","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/jnnp.2009.191239","article-title":"A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK","volume":"81","author":"Martin","year":"2010","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001675","article-title":"Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy\/tropical spastic paraparesis","volume":"6","author":"Martin","year":"2012","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0295","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-015-0031-1","article-title":"Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: A feasibility study","volume":"1","author":"Martin","year":"2015","journal-title":"Pilot Feasibility Study"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0300","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13365-016-0484-x","article-title":"Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM\/TSP: What is its relevance as a prognostic marker for neurologic disease?","volume":"23","author":"Martins","year":"2017","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0305","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/onc.2010.537","article-title":"Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: Viral infectivity, Tax, HBZ and therapy","volume":"30","author":"Matsuoka","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0310","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.coviro.2013.08.010","article-title":"Human T-cell leukemia virus type 1: Replication, proliferation and propagation by Tax and HTLV-1 bZIP factor","volume":"3","author":"Matsuoka","year":"2013","journal-title":"Current Opinion in Virology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0315","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s004010050903","article-title":"Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy\/tropical spastic paraparesis: Double staining of immunohistochemistry and polymerase chain reaction in situ hybridization","volume":"96","author":"Matsuoka","year":"1998","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0320","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2016.10.030","article-title":"HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): A comparative study to identify factors that influence disease progression","volume":"371","author":"Matsuura","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0325","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000054813","article-title":"Human T cell lymphotropic virus type 1-associated myelopathy in S\u00e3o Paulo, Brazil: Epidemiologic and clinical features of a university hospital cohort","volume":"21","author":"Milagres","year":"2002","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0330","article-title":"Interferon-\u03b3 promotes inflammation and development of T-cell lymphoma in HTLV-1 bZIP factor transgenic mice","volume":"11","author":"Mitagami","year":"2015","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0002-9394(14)73974-1","article-title":"Uveitis associated with human T-cell lymphotropic virus type I","volume":"114","author":"Mochizuki","year":"1992","journal-title":"American Journal of Ophthalmology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0340","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(89)91793-5","article-title":"HTLV-1 and polymyositis in Jamaica","volume":"334","author":"Morgan","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0345","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7326\/0003-4819-111-7-555","article-title":"Sexual transmission of human T-lymphotropic virus type I (HTLV-I)","volume":"111","author":"Murphy","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0350","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3109\/13550289809114225","article-title":"Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM\/TSP","volume":"4","author":"Nagai","year":"1998","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0355","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ana.10065","article-title":"Increased HTLV-I proviral load and preferential expansion of HTLV-I tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM\/TSP","volume":"50","author":"Nagai","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0360","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2169\/internalmedicine.52.0869","article-title":"Cerebrospinal fluid neopterin, but not osteopontin, is a valuable biomarker for the treatment response in patients with HTLV-I-associated myelopathy","volume":"52","author":"Nagai","year":"2013","journal-title":"Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0365","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/13550289509111010","article-title":"HTLV-I-associated myelopathy: Analysis of 213 patients based on clinical features and laboratory findings","volume":"1","author":"Nakagawa","year":"1995","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0370","doi-asserted-by":"crossref","DOI":"10.3109\/13550289609146899","article-title":"Therapeutic trials in 200 patients with HTLV-I-associated myelopathy\/ tropical spastic paraparesis","volume":"2","author":"Nakagawa","year":"1996","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0375","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jneuroim.2004.10.011","article-title":"CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha","volume":"159","author":"Narikawa","year":"2005","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0380","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(89)90038-X","article-title":"Chronic inflammatory arthropathy associated with HTLV-I","volume":"1","author":"Nishioka","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0385","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.41.3.457","article-title":"Neopterin in cerebrospinal fluid: A useful marker for diagnosis of HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"41","author":"Nomoto","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0390","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1423-0410.1984.tb00083.x","article-title":"A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: Seroconversion in recipients","volume":"46","author":"Okochi","year":"1984","journal-title":"Vox Sanguinis"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0395","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archneur.63.11.1560","article-title":"Natural history of human T-lymphotropic virus 1\u2013associated myelopathy","volume":"63","author":"Olindo","year":"2006","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0400","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/01.WNL.0000096011.92542.DA","article-title":"Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study","volume":"61","author":"Orland","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.pharmthera.2020.107669_bb0405","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0410","first-page":"271","article-title":"HTLV-I associated myelopathy (HAM), treatment trials, retrospective survey and clinical laboratory findings","volume":"3","author":"Osame","year":"1990","journal-title":"Hematology Review"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0415","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0420","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/01.wnl.0000251300.24540.c4","article-title":"Differentiation of HAM\/TSP from patients with multiple sclerosis infected with HTLV-I","volume":"68","author":"Puccioni-Sohler","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.pharmthera.2020.107669_bb0425","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3389\/fmicb.2019.00999","article-title":"Mother-to-child HTLV-1 transmission: Unmet research needs","volume":"10","author":"Rosadas","year":"2019","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/apmr.2001.9396","article-title":"Validity and reliability comparison of 4 mobility measures in patients presenting with neurologic impairment","volume":"82","author":"Rossier","year":"2001","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0435","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1086\/380101","article-title":"Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"189","author":"Saito","year":"2004","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0440","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-6-19","article-title":"In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"6","author":"Saito","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0445","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S1473-3099(16)30252-3","article-title":"Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: A nationwide retrospective cohort analysis","volume":"16","author":"Satake","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002479","article-title":"CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"7","author":"Sato","year":"2013","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0460","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3389\/fmicb.2018.01651","article-title":"Proposal of classification criteria for HTLV-1-associated myelopathy\/tropical spastic paraparesis disease activity","volume":"9","author":"Sato","year":"2018","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0455","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1704827","article-title":"Mogamulizumab (anti-CCR4) in HTLV-1\u2013associated myelopathy","volume":"378","author":"Sato","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001274","article-title":"HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo","volume":"7","author":"Satou","year":"2011","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0470","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ptj\/77.1.19","article-title":"Reliability of impairment and physical performance measures for persons with Parkinson\u2019s disease","volume":"77","author":"Schenkman","year":"1997","journal-title":"Physical Therapy"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.conb.2019.11.019","article-title":"An update on fluid biomarkers for neurodegenerative diseases: Recent success and challenges ahead","volume":"61","author":"Simr\u00e9n","year":"2019","journal-title":"Current Opinion in Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0480","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/167.1.57","article-title":"Heterosexual transmission of human T cell leukemia\/lymphoma virus type I among married couples in southwestern Japan: An initial report from the Miyazaki cohort study","volume":"167","author":"Stuver","year":"1993","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0485","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ijc.2910490508","article-title":"Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I","volume":"49","author":"Takahashi","year":"1991","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0490","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/13550280390173418","article-title":"Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis","volume":"9","author":"Takenouchi","year":"2003","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.02110","article-title":"Cerebrospinal fluid CXCL10 as a candidate surrogate marker for HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"10","author":"Tamaki","year":"2019","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0500","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jns.2017.08.3243","article-title":"Spinal cord anteroposterior atrophy in HAM\/TSP: Magnetic resonance imaging and neuropathological analyses","volume":"381","author":"Taniguchi","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.11.009","article-title":"The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis","volume":"228","author":"Tarokhian","year":"2017","journal-title":"Virus Research"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0510","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-3-63","article-title":"Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: A randomized trial","volume":"3","author":"Taylor","year":"2006","journal-title":"Retrovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0515","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00007890-200301150-00019","article-title":"Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor","volume":"75","author":"Toro","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0520","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1212-4","article-title":"Real-world clinical course of HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Japan","volume":"14","author":"Tsutsumi","year":"2019","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0525","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: Clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0530","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00005072-199307000-00010","article-title":"Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy","volume":"52","author":"Umehara","year":"1993","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0535","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00005072-199401000-00009","article-title":"Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy","volume":"53","author":"Umehara","year":"1994","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0540","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13550280701258431","article-title":"Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy","volume":"13","author":"Umehara","year":"2007","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0545","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/(SICI)1097-0215(19990909)82:6<832::AID-IJC11>3.0.CO;2-P","article-title":"Mother-to-child transmission of human T-cell-leukemia\/lymphoma virus type I: Implication of high antiviral antibody titer and high proviral load in carrier mothers","volume":"82","author":"Ureta-Vidal","year":"1999","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0550","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.apmr.2004.02.010","article-title":"Assessing walking ability in subjects with spinal cord injury: Validity and reliability of 3 walking tests","volume":"86","author":"Van Hedel","year":"2005","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0555","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1086\/342953","article-title":"Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"186","author":"Vine","year":"2002","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0560","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/jvi.69.5.2863-2868.1995","article-title":"Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy","volume":"69","author":"Wattel","year":"1995","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0565","first-page":"382","article-title":"Human T lymphotropic virus type 1, HTLV-1","volume":"64","author":"World Health Organization (WHO)","year":"1989","journal-title":"Weekly Epidemiological Record"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0570","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2016.08.012","article-title":"HTLV-1 induces a Th1-like state in CD4+ CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM\/TSP","volume":"304","author":"Yamano","year":"2017","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0575","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fmicb.2012.00389","article-title":"Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy\/tropical spastic paraparesis","volume":"3","author":"Yamano","year":"2012","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0580","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood.V99.1.88","article-title":"Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-associated myelopathy (HAM\/TSP)","volume":"99","author":"Yamano","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0585","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20032042","volume":"199","author":"Yamano","year":"2004","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0590","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1172\/JCI23913","article-title":"Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I\u2013associated neuroimmunological disease","volume":"115","author":"Yamano","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006517","article-title":"Abnormally high levels of virus-infected IFN-\u03b3+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder","volume":"4","author":"Yamano","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0600","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-510X(96)05319-1","article-title":"Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy\/tropical spastic paraparesis: A combined clinical, virological and immunological study","volume":"147","author":"Yamasaki","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0605","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/infdis\/jiu438","article-title":"Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy","volume":"211","author":"Yamauchi","year":"2015","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0615","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1809779","article-title":"Risk of human T-cell leukemia virus type 1 infection in kidney transplantation","volume":"380","author":"Yamauchi","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0610","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jnnp-2019-321955","article-title":"Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy\/tropical spastic paraparesis treated with steroids","volume":"91","author":"Yamauchi","year":"2019","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0620","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.immunol.19.1.475","article-title":"Multiple viral strategies of HTLV-1 for dysregulation of cell growth control","volume":"19","author":"Yoshida","year":"2001","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0625","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2169\/internalmedicine.47.1284","article-title":"Incidence and clinical significances of human T-cell lymphotropic virus type I-associated myelopathy with T2 hyperintensity on spinal magnetic resonance images","volume":"47","author":"Yukitake","year":"2008","journal-title":"Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107669_bb0630","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"Journal of Neuroinflammation"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:08:11Z","timestamp":1759010891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820301996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":126,"alternative-id":["S0163725820301996"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107669","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) focusing on clinical and laboratory biomarkers","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107669"}}